NEW YORK (GenomeWeb News) – Sequenom shareholders this week filed suit against the company and several individual current and former executives in relation to the company's mishandling of data surrounding its non-invasive test for fetal gene and chromosome abnormalities.

The complaint, filed Monday in the US District Court for the Southern District of California, alleges breach of fiduciary duties against a number of current and ex-officials, and levels charges of insider stock trading against one of the former officials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.